Endo halts Rapinyl trial early, plans submission
This article was originally published in Pharmaceutical Approvals Monthly
Endo may file an NDA for its cancer pain management drug Rapinyl based on highly significant Phase III interim results, firm says Dec. 17. The 61 patients given the oral, fast-dissolving fentanyl tablet, licensed from Orexo AB in 2004, showed a statistically significant difference in the primary endpoint, Sum of Pain Intensity Difference from baseline to 30 minutes, and secondary endpoints. Results were seen as early as 10 minutes. Endo is terminating enrollment in the double-blind crossover portion of the trial based on the interim efficacy analysis, but will continue enrollment in the safety portion and a second Phase III trial to meet requirements for additional safety data...
You may also be interested in...
In its “robust, holistic hub” online, firms in the VMS product supply chain can determine their needs, “by product, solution or delivery formats,” and use a “comprehensive and unique portfolio” to “turn natural sources into shelf-ready products.”
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.